MX2019009229A - Novedosas variantes enzimaticas que degradan la nicotina. - Google Patents

Novedosas variantes enzimaticas que degradan la nicotina.

Info

Publication number
MX2019009229A
MX2019009229A MX2019009229A MX2019009229A MX2019009229A MX 2019009229 A MX2019009229 A MX 2019009229A MX 2019009229 A MX2019009229 A MX 2019009229A MX 2019009229 A MX2019009229 A MX 2019009229A MX 2019009229 A MX2019009229 A MX 2019009229A
Authority
MX
Mexico
Prior art keywords
degrading enzyme
enzyme variants
novel nicotine
nicotine degrading
variants
Prior art date
Application number
MX2019009229A
Other languages
English (en)
Inventor
C Reed Charles
Stone Everett
W Kalnik Matthew
Thisted Thomas
Rodnick-Smith Max
Original Assignee
Antidote Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Antidote Therapeutics Inc filed Critical Antidote Therapeutics Inc
Publication of MX2019009229A publication Critical patent/MX2019009229A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/0004—Oxidoreductases (1.)
    • C12N9/0006—Oxidoreductases (1.) acting on CH-OH groups as donors (1.1)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/0004—Oxidoreductases (1.)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Addiction (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Detergent Compositions (AREA)

Abstract

Se describen variantes enzimáticas que degradan la nicotina que exhiben una mayor actividad de degradación de la nicotina y/o una menor inmunogenicidad en comparación con las enzimas NicA2 y NOX de tipo silvestre, composiciones que comprenden las variantes y métodos que las utilizan.
MX2019009229A 2017-02-03 2018-02-02 Novedosas variantes enzimaticas que degradan la nicotina. MX2019009229A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762454331P 2017-02-03 2017-02-03
US201762535507P 2017-07-21 2017-07-21
PCT/US2018/016664 WO2018144879A1 (en) 2017-02-03 2018-02-02 Novel nicotine degrading enzyme variants

Publications (1)

Publication Number Publication Date
MX2019009229A true MX2019009229A (es) 2019-12-11

Family

ID=61193218

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2019009229A MX2019009229A (es) 2017-02-03 2018-02-02 Novedosas variantes enzimaticas que degradan la nicotina.

Country Status (10)

Country Link
US (2) US11597916B2 (es)
EP (1) EP3577218A1 (es)
JP (1) JP2020506709A (es)
KR (1) KR102551403B1 (es)
CN (1) CN110520527A (es)
AU (1) AU2018215456A1 (es)
BR (1) BR112019015788A2 (es)
CA (1) CA3052928A1 (es)
MX (1) MX2019009229A (es)
WO (1) WO2018144879A1 (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2018215456A1 (en) 2017-02-03 2019-08-22 Antidote Therapeutics, Inc. Novel nicotine degrading enzyme variants
WO2019126364A2 (en) * 2017-12-19 2019-06-27 The Scripps Research Institute Compositions and methods related to nicotine addiction and cessation
WO2020027970A1 (en) 2018-08-02 2020-02-06 Antidote Therapeutics, Inc. Novel nicotine degrading enzyme variants
US11331020B2 (en) 2020-02-06 2022-05-17 Trustees Of Boston University Enzyme-based electrochemical nicotine biosensor
WO2021221752A2 (en) 2020-02-06 2021-11-04 Trustees Of Boston University High throughput assay for identifying microbial redox enzymes
US11801000B2 (en) 2021-04-30 2023-10-31 Trustees Of Boston University Hormone electrochemical biosensor
CN116622792B (zh) * 2022-10-19 2024-03-08 修实生物医药(南通)有限公司 一种使用酶催化合成（s）-烟碱的方法

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1712532A (zh) * 2004-06-24 2005-12-28 上海交通大学 猪单胺氧化酶b蛋白编码序列
CN102131813B (zh) * 2008-06-24 2014-07-30 科德克希思公司 用于制备基本上立体异构纯的稠合二环脯氨酸化合物的生物催化方法
US20150087028A1 (en) * 2012-03-12 2015-03-26 Codexis, Inc. Cbh1a variants
KR101423952B1 (ko) * 2012-10-10 2014-08-06 고려대학교 산학협력단 바이오제닉 아민의 함량 분석용 단백질 및 그 제조방법
CN103012572B (zh) * 2012-12-05 2013-11-27 北京师范大学 一种降低烟草尼古丁含量的基因及应用
CN107613762A (zh) * 2015-05-05 2018-01-19 北卡罗莱纳州立大学 减少烟草中的烟草特异性亚硝胺nnk的方法和组合物
EP3331526A4 (en) 2015-08-04 2019-04-24 The Scripps Research Institute NICOTIN-DEGREEING ENZYMES FOR THE TREATMENT OF NICOTINE DEPENDENCE AND NICOTINE POISONING
CN115806947A (zh) 2016-04-01 2023-03-17 上海交通大学 一种酶及其应用
AU2018215456A1 (en) 2017-02-03 2019-08-22 Antidote Therapeutics, Inc. Novel nicotine degrading enzyme variants
WO2019126364A2 (en) 2017-12-19 2019-06-27 The Scripps Research Institute Compositions and methods related to nicotine addiction and cessation
WO2020027970A1 (en) 2018-08-02 2020-02-06 Antidote Therapeutics, Inc. Novel nicotine degrading enzyme variants

Also Published As

Publication number Publication date
CA3052928A1 (en) 2018-08-09
US11597916B2 (en) 2023-03-07
AU2018215456A1 (en) 2019-08-22
WO2018144879A1 (en) 2018-08-09
US20230416697A1 (en) 2023-12-28
CN110520527A (zh) 2019-11-29
US20200224176A1 (en) 2020-07-16
KR20190129038A (ko) 2019-11-19
BR112019015788A2 (pt) 2020-03-17
EP3577218A1 (en) 2019-12-11
KR102551403B1 (ko) 2023-07-11
JP2020506709A (ja) 2020-03-05

Similar Documents

Publication Publication Date Title
MX2019009229A (es) Novedosas variantes enzimaticas que degradan la nicotina.
MX2018014890A (es) Composiciones de limpieza que comprenden enzimas.
MX2023000731A (es) Composiciones utiles para enzimas de internalizacion.
MX2016001315A (es) Variantes de enzimas.
MX2018012394A (es) Variantes de polipeptido ph20, formulaciones y usos de las mismas.
EP3957711A3 (en) Detergent composition comprising amylase and protease variants
WO2018109174A3 (en) Il-11 antibodies
EP4219704A3 (en) Aprl-clade protease variants and uses thereof
EP4234693A3 (en) Bacillus gibsonii-clade serine proteases
WO2018109170A3 (en) Il-11ra antibodies
EA201400031A1 (ru) Стабильные составы на основе фермента, разрушающего хиалуронан
MX371497B (es) Composiciones y metodos que comprenden una variante de enzima lipolitica.
MX2016008448A (es) Conjugados de var2csa-farmaco.
MX2017004617A (es) Variantes estabilizadas de alfa amilasa y su uso.
MX2010004674A (es) Variantes de alfa-amilasa con propiedades alteradas.
WO2015004211A3 (en) Mevalonate diphosphate decarboxylase variants
EP2575452A4 (en) ANTIMICROBIAL COMPOSITIONS
EP3636744A4 (en) LACTOBACILLUS CURVATUS WIKIM55, EFFECTIVE TO PROMOTE HAIR GROWTH AND COMPOSITION WITH IT
MX2018016037A (es) Variantes de lipasa y composiciones que comprenden tensioactivo y variante de lipasa.
WO2017123610A3 (en) Bacteria engineered to detoxify deleterious molecules
PH12018502656A1 (en) Engineered beta-glucosidases and glycosylation methods
MX2017014890A (es) Metodos de produccion de acetolactato-descarboxilasa (aldc).
EA201590796A1 (ru) Фибринолитические композиции, включающие бромелаин и наттокиназу, для предотвращения и лечения флеботромботических состояний
EP3259350A4 (en) Multi-domain enzymes having cutinase activity, compositions comprising same and uses thereof
MX2022001518A (es) Composiciones que comprenden enzimas digestivas.